Central Pharmaceuticals (DHA:CENTRALPHL) Net Income From Continuing Operations : BDT-68.10 Mil (TTM As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is Central Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Central Pharmaceuticals's net income from continuing operations for the three months ended in Sep. 2022 was BDT-9.08 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2022 was BDT-68.10 Mil.

Central Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Central Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Central Pharmaceuticals Net Income From Continuing Operations Chart

Central Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Income From Continuing Operations

Get a 7-Day Free Trial

57.10

-1,107.00

-8.47

-68.25

-43.96

Central Pharmaceuticals Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Jun23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-12.62	-9.27	-37.12	-9.08	-

Central Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-68.10 Mil.

Central Pharmaceuticals (DHA:CENTRALPHL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Central Pharmaceuticals Ltd (DHA:CENTRALPHL) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216

Website

https://www.centralphl.com

Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished formulation products for general people, hospitals, clinics, government organizations, corporations, and other non-government organizations. Its product portfolio encompasses therapeutic categories including gastrointestinal, anti-infective, vitamins and minerals, allergy cough and cold, analgesic and musculoskeletal, dermatological, oral rehydration salt, and others. The products are in the dosage forms of tablets, capsules, liquid, and ointments.

Central Pharmaceuticals (DHA:CENTRALPHL) Headlines

No Headlines